Yesterday's Q3 results show that Bristol-Myers Squibb
For its Q3, Bristol reported a 73% increase in EPS, when adjusting for non-recurring items, compared to its year-ago quarter. Net sales were up 22% over the same time frame. Of that 22%, 4% is attributable to price increases, 3% is related to foreign currency translation, and 15% is related to selling more drugs. Among the company's key drivers were its blood thinner Plavix, which the company sells with Sanofi-Aventis
The outlook for Bristol shareholders is favorable for multiple reasons. The drugmaker continues to build a strong pipeline for future growth. Key contributors to this pipeline include Ixempra, Erbitux, and the acquisition of Adnexus Therapeutics. Ixempra, a treatment for breast cancer, was granted approval by the FDA this month, while Erbitux, another oncology drug which the company has partnered with ImClone
Aside from its robust pipeline, Bristol has made positive strides in terms of improving its operational efficiency. Alliances with Pfizer
For related Foolishness about anticancer therapies, check out:
Looking to improve the pipeline of stocks making it into your portfolio? The Gardners can help you with their market-beating Stock Advisor newsletter service. You can check out their recommendations with a 30-day free trial.